What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to furnish investors with unaudited historical key product revenue information, both actual and pro forma (as if the Allergan acquisition had occurred earlier), to help them analyze AbbVie's financial performance, particularly in light of the recently completed acquisition of Allergan.

Why is the pro forma financial information important for investors?

The pro forma financial information is important because it provides a 'look-back' view of revenue as if AbbVie and Allergan had been combined since the beginning of 2019. This allows investors to better understand the combined revenue trends and the potential scale of the integrated business, facilitating more meaningful comparisons and analysis than looking at the standalone companies separately for part of the period.

When did AbbVie acquire Allergan?

AbbVie's acquisition of Allergan plc officially closed on May 8, 2020.

Where can I find the detailed financial information mentioned in this report?

The detailed unaudited financial information related to the Allergan acquisition is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

ABBV 8-K: Earnings & Results

Summary

AbbVie Inc. (ABBV) filed an 8-K on July 29, 2020, primarily to furnish unaudited financial information related to its acquisition of Allergan plc, which closed on May 8, 2020. The filing provides historical key product revenues for the quarters within 2019 and the first quarter of 2020. Crucially, it also presents comparable key product revenue data as if the Allergan acquisition had occurred on January 1, 2019. This pro forma information is vital for investors to understand the combined entity's revenue performance and trends prior to the official close date. It allows for a more accurate assessment of the integrated business's financial trajectory and the potential impact of the Allergan acquisition on AbbVie's revenue streams, enabling better comparisons and forward-looking analysis.

Key Highlights

1AbbVie filed an 8-K on July 29, 2020, providing financial information post-Allergan acquisition.
2The filing includes unaudited historical key product revenue data for 2019 and Q1 2020.
3Key unaudited pro forma financial information is provided, presenting revenues as if the Allergan acquisition closed on January 1, 2019.
4This pro forma data is intended to offer investors a clearer view of combined revenue performance.
5The Allergan acquisition officially closed on May 8, 2020.
6Exhibit 99.1 contains the furnished financial information.
7The CFO, Robert A. Michael, signed the report.

AbbVie Inc. 8-K Report, Financial Results (Jul 29, 2020)

Summary

Key Highlights

Frequently Asked Questions